Africa's No.1 Healthcare, Pharma & Biotech Industry Magazine
SWITZERLAND – Pharmaceutical giant Roche will acquire Good Therapeutics, reeling in its lead program six years after the Seattle startup was founded to design drugs that operate only where needed…
Read More
SWITZERLAND- An artificial intelligence model has shown to be much more accurate than clinicians in diagnosing pediatric ear infections in the first head-to-head comparison of its kind. The model was created…
Read More
SWITZERLAND- The first digital polymerase chain reaction (PCR) machine from Roche has been made available for purchase, according to Swiss Pharma. This next-generation system is made to precisely measure minute…
Read More
SWITZERLAND- According to the Swiss medicine authority Swissmedic, the country’s first bivalent Covid-19 booster vaccine has been provisionally permitted. Swissmedic has said that Moderna’s COVID-19 mRNA-1273.214 vaccine, known as Spikevax,…
Read More
SWITZERLAND- The European Commission (EC) has authorized Scemblix® (asciminib) for the treatment of adult patients with chronic myeloid leukemia. This is in patients with the Philadelphia chromosome in the chronic…
Read More
SWITZERLAND- The World Health Organization (WHO) has released two monoclonal antibodies as one of its top recommendations as part of its first Ebola virus disease treatment guidelines. The recommendation comes…
Read More
SWITZERLAND – Roche has launched a new dual antigen and antibody diagnostic test for hepatitis C, which the Swiss pharmaceuticals company says will give an earlier diagnosis of the virus.…
Read More
SWITZERLAND –Novartis has announced a new organizational structure and operating model with the goal of achieving US$1 billion in cost savings by 2024, as well as changes in executive leadership…
Read More
SWITZERLAND – Sandoz, a Novartis division, has acquired Coalesce Product Development Limited, a medical and drug delivery device development company based in the United Kingdom. Sandoz has acquired Coalesce’s capabilities…
Read More
SWITZERLAND – Voyager Therapeutics has secured a license option agreement in a potentially US$1.8 billion deal with Novartis. Novartis will be able to use the gene therapy company’s capsid discovery…
Read More